BioVersys AG (SWX:BIOV)

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Other Revenue	1.31	1.21	1.14
Revenue	1.31	1.21	1.14
Revenue Growth (YoY)	-	6.50%	-
Gross Profit	1.31	1.21	1.14
Selling, General & Admin	6.41	7	4.02
Research & Development	12.61	12.95	14.83
Operating Expenses	19.02	19.94	18.84
Operating Income	-17.71	-18.73	-17.7
Interest Expense	-1.02	-1.03	-0.7
Interest & Investment Income	0.26	0.5	0.48
Currency Exchange Gain (Loss)	-0.04	0.13	-0.16
Other Non Operating Income (Expenses)	-0.84	0.42	-0.22
Pretax Income	-19.36	-18.72	-18.3
Net Income	-19.36	-18.72	-18.3
Net Income to Common	-19.36	-18.72	-18.3
Shares Outstanding (Basic)	4	3	3
Shares Outstanding (Diluted)	4	3	3
Shares Change (YoY)	-	11.60%	-
EPS (Basic)	-4.34	-5.62	-6.13
EPS (Diluted)	-4.34	-5.62	-6.13
Free Cash Flow	-16.71	-15.61	-11.7
Free Cash Flow Per Share	-3.75	-4.68	-3.92
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-1353.25%	-1544.11%	-1554.17%
Profit Margin	-1478.84%	-1543.20%	-1606.76%
Free Cash Flow Margin	-1276.39%	-1287.06%	-1027.57%
EBITDA	-17.65	-18.67	-17.65
D&A For EBITDA	0.06	0.06	0.06
EBIT	-17.71	-18.73	-17.7
Revenue as Reported	1.31	1.21	1.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.